Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Fins are out..

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 13, 2022 8:05am

114 Views

Post# 34599464

RE:RE:RE:Fins are out..

"We are currently exploring alternatives to redeem the senior convertible notes issued in June 2018, which become due in June 2023."
I believe this is a new statement, they had about 40 millions last Q compared with 34 millions now.

palinc2000 wrote: The PR shows very little enthusiasm ....Lets hope that the CC shows more life

palinc2000 wrote: Nice increase in Egrift a sales..F -8 formulation delayed for an unknown period due to a technical problem ......thus Nash trial conveniently paused for an unknown period ......
No positive surprises in the PR